Amyloid and Tau Co-pathology in Parkinson Disease and Atypical Parkinsonism - PubMed
3 hours ago
- #Parkinson's Disease
- #Amyloid-Tau Co-pathology
- #Neurodegenerative Disorders
- Amyloid and tau co-pathology in Parkinson's Disease (PD) and atypical parkinsonism (AP) affects progression, motor phenotype, and cognitive status.
- Neuropathology, neuroimaging, and fluid biomarkers highlight the role of Alzheimer's disease (AD) co-pathology in PD and AP.
- Aβ and tau co-pathologies contribute to cortical atrophy and network disruption in PD and AP.
- Diffuse and neuritic Aβ plaques are uncommon in non-demented PD (10%), intermediate in PD-dementia (30-40%), and frequent in Dementia with Lewy Bodies (60-80%).
- Aβ fluid biomarkers may predict clinical trajectory and cognitive decline in PD and DLB.
- Multimodal assessment (molecular imaging, structural/functional MRI, fluid biomarkers) is crucial for differential diagnosis and outcome prediction in AP disorders.
- Plasma tau biomarkers and seed-amplification assays are promising approaches for PD and AP.